Cart
sales@molnova.com
AG18
CAS No. 118409-57-7
AG18( RG-50810 | RG-50858 | TX 825 | Tyrphostin 23 | Tyrphostin AG-18 )
Catalog No. M10624 CAS No. 118409-57-7
AG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 35 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 49 | In Stock |
|
| 25MG | 112 | In Stock |
|
| 50MG | 212 | In Stock |
|
| 100MG | 320 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAG18
-
NoteResearch use only, not for human use.
-
Brief DescriptionAG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 35 μM.
-
DescriptionAG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 35 μM.
-
In Vitro10 μM tyrphostin 23 causes significant inhibition of the cell proliferation caused by 1 nM and 1μM ghrelin. Tyrphostin 23 (T23) is a well-known inhibitor of protein tyrosine kinases and has been considered as potential anti-cancer drug. T23 is reported to acutely stimulate the glycolytic flux in primary cultured astrocytes. Tyrphostin 23 stimulates glycolytic flux in cultured astrocytes. Mitochondrial metabolism of brain astrocytes is accelerated by Tyrphostin 23 exposure.
-
In Vivo——
-
SynonymsRG-50810 | RG-50858 | TX 825 | Tyrphostin 23 | Tyrphostin AG-18
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number118409-57-7
-
Formula Weight186.17
-
Molecular FormulaC10H6N2O2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 37 mg/mL (198.74 mM); DMSO: 37 mg/mL (198.74 mM)
-
SMILESN#C/C(C#N)=C/C1=CC=C(O)C(O)=C1
-
Chemical Name2-[(3,4-dihydroxyphenyl)methylene]-propanedinitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gazit A, et al. J Med Chem, 1989, 32(10), 2344-2352.
molnova catalog
related products
-
(Rac)-JBJ-04-125-02
JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
-
CHMFL-EGFR-202
CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).
-
SKLB 1028
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
